Measurement of matrix metalloproteinases and their tissue inhibitors in serum produces doubtful results

Journal of Infectious Diseases

Volumn 198, Issue 11, 2008, Pages 1722-1723

  Jung, Klaus ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; MATRIX METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

BLOOD SAMPLING; ENZYME RELEASE; LETTER; LEUKOCYTE; MALARIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTE;

ADULT; BLOOD SPECIMEN COLLECTION; HUMANS; MALARIA; MATRIX METALLOPROTEINASES; SPECIMEN HANDLING; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 56649120595     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/593070     Document Type: Letter

References (10)

1. Dietmann A, Helbok R, Lackner P, et al. Matrix metalloproteinases and their tissue inhibitors (TIMPs) in Plasmodium falciparum malaria: serum levels of TIMP-1 are associated with disease severity. J Infect Dis 2008; 197:1614 -20.
2. Makowski GS, Ramsby ML. Use of citrate tominimize neutrophil matrix metalloproteinase-9 in human plasma. Anal Biochem 2003; 322:283-6.
3. Holten-Andersen MN, Schrohl AS, Brunner N, Nielsen HJ, Hogdall CK, Hogdall EV. Evaluation of sample handling in relation to levels of tissue inhibitor of metalloproteinases-1 measured in blood by immunoassay. Int J Biol Markers 2003; 18:170-6.
4. Gerlach RF, Uzuelli JA, Souza-Tarla CD, Tanus-Santos JE. Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Anal Biochem 2005; 344:147-9.
5. Jung K, Meisser A, Bischof P. Blood sampling as critical preanalytical determinant to use circulating MMP and TIMP as surrogate markers for pathological processes. Int J Cancer 2005; 116:1000 -1.
6. Mannello F, Tonti GA, Tanus-Santos JE, Gerlach RF. Silicate increases the release of MMP-9 forms in peripheral blood: why gelatin zymography differs significantly in citrate plasma and serum obtained with or without clot activators. Clin Chem 2007; 53:1981-2.
7. Jung K, Klotzek S, Stephan C, Mannello F, Lein M. Impact of blood sampling on the circulating matrix metalloproteinases 1, 2, 3, 7, 8, and 9. Clin Chem 2008; 54:772- 4.
8. Mannello F, Tonti GA. Gelatinase concentrations and zymographic profiles in human breast cancer: matrix metalloproteinases circulating in plasma are better markers for the subclassification and early prediction of cancer: the coagulation/fibrinolysis pathways alter the release, activation and recovery of different gelatinases in serum. Int J Cancer 2007; 121:216-8.
9. Tworoger SS, Hankinson SE. Use of biomarkers in epidemiologic studies: minimizing the influence of measurement error in the study design and analysis. Cancer Causes Control 2006; 17:889 -99.
10. Wurtz SO, Moller S, Mouridsen H, Hertel PB, Friis E, Brunner N. Plasma and serum levels of tissue inhibitor of metalloproteinases-1 are associated with prognosis in node-negative breast cancer: a prospective study. Mol Cell Proteomics 2008; 7:424 -30.